Overexpression of long noncoding RNA PTPRG-AS1 is associated with poor prognosis in epithelial ovarian cancer
| Autor: | Xue-Ying Ren, Wei-Bin Yang, Yun Tian |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Medicine (General) RNA long noncoding endocrine system diseases Carcinoma ovarian epithelial 03 medical and health sciences 0302 clinical medicine R5-920 Internal medicine Carcinoma Humans Medicine Clinical significance Stage (cooking) 030304 developmental biology Ovarian Neoplasms Regulation of gene expression 0303 health sciences Receptor-Like Protein Tyrosine Phosphatases Class 5 business.industry Proportional hazards model General Medicine medicine.disease Prognosis Long non-coding RNA Antisense RNA Gene Expression Regulation Neoplastic Tumor progression 030220 oncology & carcinogenesis Female business |
| Zdroj: | Revista da Associação Médica Brasileira, Vol 66, Iss 7, Pp 948-953 (2020) Revista da Associação Médica Brasileira v.66 n.7 2020 Revista da Associação Médica Brasileira Associação Médica Brasileira (AMB) instacron:AMB |
| ISSN: | 1806-9282 |
| Popis: | SUMMARY OBJECTIVE Long noncoding RNAs (lncRNAs) have been shown to play a critical role in tumor progression. Abnormal expression of LncRNA PTPRG antisense RNA 1 (PTPRG-AS1) has been reported in several tumors. Hence, we aimed to determine the expression and clinical significance of PTPRG-AS1 in epithelial ovarian cancer (EOC) patients. METHODS The expressions of PTPRG-AS1 were assessed in 184 pairs of EOC tumor specimens and adjacent normal tissues. The levels of target lncRNAs and GAPDH were examined using standard SYBR-Green methods. The relationships between the expressions of PTPRG-AS1 and the clinicopathological features were analyzed using the chi-square test. Multivariate analysis using the Cox proportional hazards model was performed to assess the prognostic value of PTPRG-AS1 in EOC patients. RESULTS We confirmed that the expressions of PTPRG-AS1 were distinctly higher in the EOC tissue compared with the adjacent non-tumor specimens (p < 0.01). Higher levels of PTPRG-AS1 in EOC patients were associated with advanced FIGO stage (p = 0.005), grade (p = 0.006), and distant metastasis (p = 0.005). Survival analyses revealed that patients with high expressions of PTPRG-AS1 had a distinctly decreased overall survival (p = 0.0029) and disease-free survival (p = 0.0009) compared with those with low expressions of PTPRG-AS1. Multivariate assays indicated that PTPRG-AS1 expression was an independent prognostic factor for both overall survival and disease-free survival in EOC (Both p < 0.05). CONCLUSIONS Our study suggests that PTPRG-AS1 may serve as a novel prognostic biomarker for EOC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|